Prostate Nodule
A prostate nodule is a discrete firm area within the prostate gland, detected either by a clinician during a digital rectal examination or as a focal abnormality on imaging. It is a finding rather than a diagnosis, and the causes range widely: benign prostatic hyperplasia commonly produces nodules, as do prior infection, inflammation, calcification, infarction, and previous treatment. Prostate cancer is also a possibility, and distinguishing between these is the entire purpose of the evaluation that follows. Modern practice has changed substantially in how this is done, with multiparametric MRI now performed before biopsy in most cases, allowing many men to avoid biopsy altogether while improving detection of the cancers that genuinely matter.
What is it?
The prostate is a walnut-sized gland sitting below the bladder and surrounding the urethra, producing fluid that forms part of semen. It is divided into zones, and this anatomy matters considerably for interpreting nodules.
The peripheral zone forms the outer and posterior portion of the gland, lying directly against the rectal wall. It is the part a clinician can feel during a digital rectal examination, and it is where the majority of prostate cancers arise. The transition zone surrounds the urethra in the centre of the gland and is where benign prostatic hyperplasia develops, enlarging over time and compressing the urethra to produce urinary symptoms. The central zone surrounds the ejaculatory ducts and is uncommonly involved by disease.
A prostate nodule is a discrete firm or focally abnormal area within this gland. The term is used in two related but distinct contexts, and it is worth separating them, because they carry different implications.
A palpable nodule is one felt on digital rectal examination as a firm, irregular, or asymmetric area within an otherwise softer gland. Because the examining finger reaches only the posterior peripheral zone, this method assesses a limited portion of the prostate and misses lesions in the anterior gland and transition zone entirely.
An imaging-detected nodule is a focal abnormality seen on MRI or, less specifically, on ultrasound or CT. MRI in particular can identify lesions anywhere in the gland, including areas the examining finger cannot reach.
The causes of a prostate nodule span benign and malignant, and benign predominates.
Benign prostatic hyperplasia is the most common cause overall. It consists of the growth of nodules of glandular and muscular tissue within the transition zone, and these are literally nodules by definition. When large or positioned toward the back of the gland, they can be palpable and can be mistaken for something more concerning. BPH is extremely common with age and is not a precursor to cancer, despite frequently coexisting with it.
Prostatitis and granulomatous prostatitis produce firm areas from inflammation and scarring. Granulomatous prostatitis in particular—which can follow infection, BCG treatment for bladder cancer, or occur without identifiable cause—produces both a firm nodule on examination and MRI appearances that closely mimic cancer, and it is one of the more common benign causes of a falsely suspicious scan.
Prostatic calcification, common with age and often the residue of prior inflammation, can produce firmness. Prostatic cysts and abscesses can present as focal abnormalities. Prostatic infarction, in which a portion of the gland loses its blood supply, produces a firm area and can also raise PSA substantially, occasionally mimicking cancer on both counts.
Post-treatment change following transurethral resection, radiotherapy, focal ablation, or other intervention produces firm and irregular areas that persist indefinitely.
Prostate cancer is the concern driving evaluation. Adenocarcinoma accounts for the great majority and arises most often in the peripheral zone. Its firmness relative to surrounding tissue is what makes it palpable when superficial enough. Less common types include ductal, neuroendocrine, and small cell carcinomas, along with rare sarcomas and lymphomas, and the prostate can occasionally be involved by bladder or rectal cancer extending into it.
Symptoms deserve careful framing, because expectations here are often mistaken. Prostate nodules, whether benign or malignant, are typically asymptomatic. Early prostate cancer in particular does not usually cause urinary symptoms, since it arises in the peripheral zone away from the urethra, whereas benign enlargement arises around the urethra and therefore does cause them. This produces a persistent and consequential misconception: men frequently assume that the absence of urinary symptoms means the absence of cancer, and that troublesome urinary symptoms indicate cancer, when the reverse relationship is closer to the truth.
Symptoms that do raise concern for more advanced disease include blood in the urine or semen, new erectile dysfunction, persistent pelvic or perineal pain, and bone pain in the back, hips, ribs, or pelvis, which can indicate metastatic spread. Fever with pain and urinary symptoms points toward prostatitis.
The evaluation of a prostate nodule has changed substantially over the past decade, and understanding the current pathway helps make sense of what is recommended.
Digital rectal examination remains part of assessment, though its role has diminished as imaging has improved. It detects abnormalities in the posterior peripheral zone and provides information about gland size and consistency. Its limitations—operator variability and access to only part of the gland—mean a normal examination does not exclude cancer, and an abnormal one does not establish it.
PSA testing measures a protein produced by prostate tissue. It is elevated in prostate cancer but also in benign enlargement, prostatitis, urinary infection, recent ejaculation, catheterisation, prostate biopsy, and vigorous cycling. It is best interpreted alongside age, gland size, and the trend over time rather than against a single fixed threshold, and derived measures including PSA density—PSA relative to prostate volume—and free-to-total PSA ratio add useful information. A raised PSA is a prompt for further assessment rather than a diagnosis, and a normal PSA does not exclude cancer, particularly with higher-grade disease that produces relatively little PSA.
Multiparametric MRI of the prostate is now central and represents the most significant change in this field. It combines anatomical imaging with diffusion-weighted and dynamic contrast-enhanced sequences to characterise the gland. Lesions are scored using the PI-RADS system on a scale from 1 to 5, where 1 and 2 indicate clinically significant cancer is unlikely, 3 is equivocal, and 4 and 5 indicate it is likely or highly likely.
Performing MRI before biopsy—rather than biopsying everyone with a raised PSA—has two major benefits demonstrated in large trials. It allows a substantial proportion of men with reassuring scans to avoid biopsy entirely, sparing them an uncomfortable procedure with real risks. And it improves detection of clinically significant cancers while reducing detection of indolent, low-grade disease that would never have caused harm but that, once found, often leads to treatment and its side effects. This shift toward finding the cancers that matter while leaving the ones that do not is the central logic of contemporary practice.
Biopsy provides tissue diagnosis and is guided by MRI findings where a target exists. It has increasingly moved from a transrectal to a transperineal approach—passing needles through the skin between the scrotum and anus rather than through the rectal wall—which substantially reduces the risk of serious infection and can be performed under local anaesthetic. Tissue is graded using the Gleason system, now generally reported as Grade Groups 1 through 5, which describes how aggressive the cancer appears under the microscope and is one of the strongest predictors of behaviour.
For men with confirmed cancer, staging depends on risk. PSMA PET-CT has become the standard for staging higher-risk disease and for detecting recurrence, and is considerably more sensitive than conventional bone scan and CT. Bone scan and CT remain in use in some settings.
Additional biomarkers and genomic tests are available and may help refine decisions in borderline situations, particularly around whether to biopsy and whether to pursue surveillance or treatment.
Important to Know
The most useful framing for a man told he has a prostate nodule is that this is the beginning of an assessment rather than a diagnosis, and that most nodules are not cancer. Care is typically coordinated by primary care clinicians and urologists, with radiology, pathology, radiation oncology, and medical oncology involved when cancer is confirmed.
Benign causes generally require no treatment for the nodule itself. Benign prostatic hyperplasia is treated according to how bothersome the urinary symptoms are, not according to gland size, and many men need nothing more than reassurance and periodic review. Where treatment is warranted, options range from medications that relax the prostate or shrink it, through minimally invasive procedures, to surgery. Bacterial prostatitis is treated with an appropriate antibiotic course, which is often prolonged. Calcification and post-treatment change need nothing.
When MRI shows a low PI-RADS score in a man without other concerning features, biopsy can often reasonably be avoided, with PSA monitoring and repeat assessment instead. This is a meaningful benefit of the current pathway and is worth understanding, since patients sometimes expect biopsy to be automatic after any abnormal finding.
Where cancer is confirmed, the single most important development in recent decades is that not all prostate cancer requires treatment. Low-risk disease—Grade Group 1, limited volume, low PSA—frequently behaves indolently, and active surveillance has become the preferred management for most such men. This involves scheduled PSA testing, periodic MRI, and repeat biopsy according to protocol, with treatment offered if the disease shows signs of progression. Large studies have shown that this approach does not compromise long-term survival while sparing many men the urinary, sexual, and bowel side effects of treatment. Active surveillance is a deliberate strategy of monitoring, not a decision to ignore the cancer, and this distinction is worth making clearly, since the term is sometimes misunderstood as doing nothing.
Intermediate and high-risk disease is treated with radical prostatectomy or radiotherapy, which have broadly comparable cancer outcomes but different side effect profiles—surgery carries a higher early risk of urinary incontinence and erectile dysfunction, while radiotherapy carries more bowel and urinary irritative effects and a small long-term risk of second cancers. Radiotherapy for higher-risk disease is often combined with a period of hormonal therapy. Focal therapies treating only the affected part of the gland are available at specialist centres for carefully selected patients and remain an area of ongoing study.
Advanced disease is treated with hormonal therapy, increasingly combined upfront with additional agents, chemotherapy in selected patients, and targeted treatments including PARP inhibitors for men with specific inherited or tumour mutations. PSMA-targeted radioligand therapy is an option in advanced disease.
Screening for prostate cancer remains an area of legitimate debate rather than settled consensus, and this is worth stating plainly. PSA screening reduces prostate cancer mortality but also detects cancers that would never have caused harm, and treatment carries meaningful side effects. Most guidelines now recommend shared decision-making, in which a man discusses his individual risk, values, and preferences with his clinician rather than being screened automatically or not at all. Men at higher risk—those of African ancestry, those with a father or brother diagnosed, and those with known BRCA2 or other high-risk mutations—are generally advised to begin these discussions earlier.
Genetic considerations have become more prominent. BRCA2 in particular is associated with both higher risk and more aggressive disease, and identifying it affects treatment options and has implications for relatives. Testing is increasingly recommended for men with metastatic, high-risk, or strongly familial disease.
Follow-up depends on the diagnosis, ranging from routine PSA monitoring for benign findings, through structured surveillance protocols, to oncologic follow-up after treatment.
Care is typically coordinated by urology, with multidisciplinary input as needed. Examination, PSA, imaging, biopsy, and clinical findings are interpreted together alongside age, general health, family history, and personal preferences rather than in isolation.
Patient education plays an important role. Understanding that most prostate nodules are not cancer, that urinary symptoms and cancer are not closely linked, that MRI before biopsy can often avoid biopsy altogether, that many prostate cancers are safely monitored rather than treated, and that screening decisions are genuinely individual all contribute to appropriate care and informed decision-making.
Red flag symptoms include blood in the urine or semen; persistent bone pain, particularly in the back, hips, ribs, or pelvis; unexplained weight loss; inability to pass urine, which is a urological emergency; new leg weakness, numbness, or difficulty walking, or new bladder or bowel incontinence, which may indicate spinal cord compression and requires immediate assessment; fever with pelvic pain and urinary symptoms; and a rapidly rising PSA. These warrant prompt or emergency evaluation depending on severity.